EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallbericht

Dupilumab for atopic dermatitis in patients with malignancies: a case report and literature review on efficacy, safety and potential mechanisms

Jiayang Li, Guan Jiang

Clinical and Experimental Dermatology · 2025

DOI: 10.1093/ced/llaf117 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Jiayang Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is a persistent inflammatory skin disease marked by intense rash and itching. Traditional treatments for moderate-to-severe AD, such as methotrexate, often cause significant side-effects. Dupilumab, a biologic therapy that inhibits the interleukin (IL)-4 and IL-13 cytokines, presents a safer alternative. A comprehensive literature review corroborates the safety and effectiveness of dupilumab in patients with AD with cancer. However, the current evidence is limited, necessitating further research. Dupilumab’s targeted mechanism, acting on IL-4 and IL-13, may also positively influence the tumour microenvironment, potentially boosting antitumour responses. Future studies should focus on assessing the long-term safety, efficacy and economic viability of dupilumab across larger and more diverse populations to better understand its dual role in managing both cancer and AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedHumansFemaleInterleukin-13MaleTreatment OutcomeMiddle AgedInterleukin-4

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedInterleukin-13Interleukin-4

Autor:innen und Institutionen

  • Department of Dermatology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Xuzhou Medical University, Xuzhou, Jiangsu, China.

Zitieren

APA

Li, J., & Jiang, G. (2025). Dupilumab for atopic dermatitis in patients with malignancies: a case report and literature review on efficacy, safety and potential mechanisms. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf117

Vancouver

Li J, Jiang G. Dupilumab for atopic dermatitis in patients with malignancies: a case report and literature review on efficacy, safety and potential mechanisms. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf117

BibTeX
@article{Li2025,
  author = {Li, Jiayang and Jiang, Guan},
  title = {Dupilumab for atopic dermatitis in patients with malignancies: a case report and literature review on efficacy, safety and potential mechanisms},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  doi = {10.1093/ced/llaf117}
}
Kostenlos starten →